Ad hoc releases are announcements pursuant to SIX Swiss Exchange Article 53 Listing Rules.
-
Ad hoc release
Test New ROOT Novartis receives FDA approval for Rhapsido® (remibrutinib), the only oral, targeted BTKi treatment for chronic spontaneous urticaria (CSU)
Ad hoc announcement pursuant to Art. 53 LRRhapsido helps to inhibit release of histamine and proinflammatory mediators by targeting BTK, offering unique approach to CSU treatment1 Well-… -
Featured NewsTest
-
Story
test content
-
Ad hoc release
Novartis receives FDA approval for Rhapsido® (remibrutinib), the only oral, targeted BTKi treatment for chronic spontaneous urticaria (CSU)
Ad hoc announcement pursuant to Art. 53 LRRhapsido helps to inhibit release of histamine and proinflammatory mediators by targeting BTK, offering unique approach to CSU treatment1 Well-… -
Press release
Novartis to launch Direct-to-Patient platform for Cosentyx® (secukinumab) in the US
Select units of Cosentyx to be made available at 55% discount off list price on direct-to-patient (DTP) platform beginning November 1, 2025DTP offering to expand to other appropriate products;… -
Press release
Novartis announces commencement of tender offer to acquire Tourmaline Bio
Basel, September 29, 2025 - Novartis today announced that Torino Merger Sub Inc., a Delaware corporation and an indirect wholly owned subsidiary of Novartis (“Purchaser”), has commenced a tender…
-
Ad hoc release
Test New ROOT Novartis receives FDA approval for Rhapsido® (remibrutinib), the only oral, targeted BTKi treatment for chronic spontaneous urticaria (CSU)
Ad hoc announcement pursuant to Art. 53 LRRhapsido helps to inhibit release of histamine and proinflammatory mediators by targeting BTK, offering unique approach to CSU treatment1 Well-… -
Ad hoc release
Novartis receives FDA approval for Rhapsido® (remibrutinib), the only oral, targeted BTKi treatment for chronic spontaneous urticaria (CSU)
Ad hoc announcement pursuant to Art. 53 LRRhapsido helps to inhibit release of histamine and proinflammatory mediators by targeting BTK, offering unique approach to CSU treatment1 Well-… -
Press release
Novartis to launch Direct-to-Patient platform for Cosentyx® (secukinumab) in the US
Select units of Cosentyx to be made available at 55% discount off list price on direct-to-patient (DTP) platform beginning November 1, 2025DTP offering to expand to other appropriate products;… -
Press release
Novartis announces commencement of tender offer to acquire Tourmaline Bio
Basel, September 29, 2025 - Novartis today announced that Torino Merger Sub Inc., a Delaware corporation and an indirect wholly owned subsidiary of Novartis (“Purchaser”), has commenced a tender… -
Press release
Novartis to showcase transformative data in advanced prostate and early breast cancer at ESMO 2025
Key data from PSMAddition has been selected for a Presidential session; data to showcase the efficacy and safety of PluvictoTM plus standard of care (SoC) versus SoC alone in PSMA+ mHSPCNATALEE five-… -
Press release
New Novartis data further support benefits of Kesimpta® in relapsing MS following switch from oral disease modifying therapies
ARTIOS Phase IIIb, open-label, single-arm, prospective study showed a substantial reduction in disease activity in people with relapsing multiple sclerosis (RMS) following switch to Kesimpta after…
-
Ad hoc release
Test New ROOT Novartis receives FDA approval for Rhapsido® (remibrutinib), the only oral, targeted BTKi treatment for chronic spontaneous urticaria (CSU)
Ad hoc announcement pursuant to Art. 53 LRRhapsido helps to inhibit release of histamine and proinflammatory mediators by targeting BTK, offering unique approach to CSU treatment1 Well-… -
Ad hoc release
Novartis receives FDA approval for Rhapsido® (remibrutinib), the only oral, targeted BTKi treatment for chronic spontaneous urticaria (CSU)
Ad hoc announcement pursuant to Art. 53 LRRhapsido helps to inhibit release of histamine and proinflammatory mediators by targeting BTK, offering unique approach to CSU treatment1 Well-… -
Ad hoc release
Novartis announces both ianalumab Phase III clinical trials met primary endpoint in patients with Sjögren’s disease
Ad hoc announcement pursuant to Art. 53 LR NEPTUNUS-1 and NEPTUNUS-2 are the first ever global phase III trials to demonstrate statistically significant reduction in disease activity for Sjögren’s… -
Ad hoc release
Novartis appoints Mukul Mehta as Chief Financial Officer, as Harry Kirsch retires after 22 years with the company
Ad hoc announcement pursuant to Art. 53 LR Mukul Mehta, currently Head of Business Planning and Analysis (BPA), Digital Finance and Tax, has been appointed Chief Financial Officer, effective March… -
Ad hoc release
Novartis reports strong Q2 with double-digit sales growth and core margin expansion; raises FY 2025 core operating income guidance
Ad hoc announcement pursuant to Art. 53 LRQ2 net sales grew +11% (cc1, +12% USD) with core operating income1 up +21% (cc, +20% USD) Sales growth driven by continued strong performance from Kisqali (+… -
Ad hoc release
Novartis verzeichnet ein starkes zweites Quartal mit zweistelligem Umsatzwachstum und erhöhter Kerngewinnmarge; Prognose für das operative Kernergebnis im Geschäftsjahr 2025 angehoben
Ad-hoc-Mitteilung gemäss Art. 53 KR Der Nettoumsatz wuchs im zweiten Quartal um +11% (kWk1, +12% USD), das operative Kernergebnis1 verbesserte sich um +21% (kWk, +20% USD)Das…
-
Statement
Vas Narasimhan named to 2025 TIME100 Health list
-
Statement
Europe talks health sovereignty — now it must deliver
-
Statement
Novartis statement on Maximum Fair Price for Entresto
-
Statement
Violence against innocent people runs counter to our work to improve human health
-
Statement
Novartis condemns the terrorist actions against people in Israel and loss of innocent lives
-
Statement
Novartis statement on collaboration and license agreement for tislelizumab with BeiGene, Ltd.
Novartis and BeiGene, Ltd. have mutually agreed to terminate the collaboration and license agreement for tislelizumab, a humanized IgG4 anti-PD-1 monoclonal antibody.
-
Story
test content
-
Story About Novartis Access to Healthcare
Test story page for non english content
-
Story
test story
-
Story
Test - Story - ContentSync - Translated content pulled from Repository
-
Story About Novartis
Test Content
Novartis announces the company’s financial results for the second quarter and first half of 2025.
-
Story About Novartis Access to Healthcare
test story content
test story contenttest story contenttest story contenttest story contenttest story contenttest story contenttest story contenttest story contenttest story content
Novartis Financial Results – Q2 2025
Novartis announces the company’s financial results for the second quarter and first half of 2025.
Novartis in Society Integrated Report 2024
The Novartis in Society Integrated Report provides an overview our business, strategy and performance, and describes how we create sustainable value for stakeholders and society.
Annual Report 2024
The Annual Report 2024, filed with the SIX Swiss Exchange in Switzerland, provides a comprehensive overview of Novartis, including our company structure, corporate governance, operating and financial results, and compensation practices.
Stories
Our research redefines the way we understand disease and develop medicines. Discover the people and stories that make it possible.
Events
Keep informed about the latest Novartis events. From upcoming congresses and conferences to special forums, explore our event calendar for ongoing opportunities to connect and engage.
